LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial.

Trial Profile

LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms LICC
  • Most Recent Events

    • 13 Jul 2015 Three-year overall survival (OS) time is now a primary end point, and duration of dosage changed from 3 years to 2 years, according to ClinicalTrials.gov record
    • 13 Jul 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.record.
    • 13 Jul 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top